Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma 177Lymphoma, Non-Hodgkin 168Lymphoma, Follicular 154Burkitt Lymphoma 146Lymphoma, Large B-Cell, Diffuse 142Lymphoma, B-Cell, Marginal Zone 135Lymphoma, Mantle-Cell 133Lymphoma, Large-Cell, Immunoblastic 115Hodgkin Disease 109Myelodysplastic Syndromes 107Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 96Congenital Abnormalities 90Multiple Myeloma 86Lymphoma, T-Cell, Cutaneous 81Lymphoma, Large-Cell, Anaplastic 76Hematologic Neoplasms 75Leukemia, Myelomonocytic, Chronic 74Waldenstrom Macroglobulinemia 73Immunoblastic Lymphadenopathy 70Leukemia, Myelomonocytic, Acute 69Sezary Syndrome 68Mycosis Fungoides 68Blast Crisis 68Leukemia, Monocytic, Acute 62Myeloproliferative Disorders 61Leukemia, Myelogenous, Chronic, BCR-ABL Positive 61

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Xeroderma Pigmentosum × Other hematologic neoplasm × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡